Brokerages Set Immuneering Co. (NASDAQ:IMRX) PT at $12.80

Shares of Immuneering Co. (NASDAQ:IMRX) have been assigned an average rating of “Hold” from the eight analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $12.80.

A number of equities analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price objective on shares of Immuneering in a research report on Monday. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. Finally, Chardan Capital reiterated a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a report on Wednesday, January 8th.

Immuneering Price Performance

NASDAQ IMRX opened at $2.01 on Thursday. Immuneering has a 12 month low of $1.00 and a 12 month high of $7.68. The stock has a market capitalization of $62.41 million, a P/E ratio of -1.02 and a beta of -0.34. The firm’s 50-day moving average is $2.05 and its two-hundred day moving average is $1.78.

Institutional Investors Weigh In On Immuneering

A number of hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new stake in shares of Immuneering during the second quarter worth approximately $492,000. Renaissance Technologies LLC purchased a new stake in shares of Immuneering in the 2nd quarter valued at approximately $447,000. HighTower Advisors LLC raised its holdings in shares of Immuneering by 21.4% in the 3rd quarter. HighTower Advisors LLC now owns 53,360 shares of the company’s stock valued at $132,000 after purchasing an additional 9,400 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Immuneering during the 2nd quarter worth $67,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Immuneering during the second quarter worth $44,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.